Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)

Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)

Background and purpose: The PRIDE trial (NOA-28; ARO-2022-12; NCT05871021) is scheduled to start recruitment in October 2023. Its primary objective is to enhance median overall survival (OS), compared to historical median OS rates, in patients with methylguanine methlyltransferase (MGMT) promotor un...

Full description

Bibliographic Details
Main Authors: Raphael Bodensohn, Daniel F. Fleischmann, Sebastian H. Maier, Vasiliki Anagnostatou, Sylvia Garny, Alexander Nitschmann, Marcel Büttner, Johannes Mücke, Stephan Schönecker, Kristian Unger, Elgin Hoffmann, Frank Paulsen, Daniela Thorwarth, Adrien Holzgreve, Nathalie L. Albert, Stefanie Corradini, Ghazaleh Tabatabai, Claus Belka, Maximilian Niyazi
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Glioblastoma
Dose escalation
FET PET
Bevacizumab
Radiation necrosis
NTCP
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630823001313

Internet

http://www.sciencedirect.com/science/article/pii/S2405630823001313

Similar Items